论文部分内容阅读
自从1952年 Markowitz 在动物实验的基础上提出肝动脉阻断治疗肝癌的概念以来,临床上广泛开展了肝动脉结扎、肝动脉栓塞、肝脏完全去动脉化治疗不能手术切除的肝癌,但其治疗效果尚欠满意。随着对肝脏正常组织和肝脏肿瘤血管分布研究的深入,近年来出现了门静脉分支血流阻断或门静脉灌注化学药物治疗肝癌的新方法,其治疗效果令人瞩目。一、肝癌的门静脉血流供应原发和继发性肝癌的癌结节血流供应是来源于肝动脉还是门静脉或者是双重血流供应,长期以来存在着争论,目前较多的作者认为是双重血流供应。1972年 Ackerman 在大鼠转移性肝癌的实验中,结扎大鼠门静脉,然后从肝动脉注
Since Markowitz put forward the concept of hepatic artery blockade for liver cancer on the basis of animal experiments in 1952, hepatic arterial ligation, hepatic artery embolization, and complete dearterialization of the liver have been widely used to treat unresectable liver cancer. Satisfactory satisfaction. With the deep research on the liver tissue and hepatic tumor blood vessel distribution, in recent years there has been a new method of portal vein blood flow block or portal vein perfusion chemotherapy for liver cancer. The therapeutic effect is remarkable. 1. The portal vein blood supply to liver cancer The supply of blood supply to the primary and secondary hepatocellular carcinoma nodules originates from the hepatic artery or the portal vein, or is a dual blood supply. There has been controversy for a long time, and many authors consider it to be double. Blood flow supply. In 1972 Ackerman’s experiment of metastatic liver cancer in rats, ligation of the rat portal vein, followed by injection from the hepatic artery